Comparing the current results to its competitors, Kura Oncology Inc reported Revenue increase in the 2 quarter 2026 by 36.54 % year on year. The sales growth was above Kura Oncology Inc 's competitors' average revenue growth of 5.57 %, achieved in the same quarter.
Kura Oncology Inc , slower than the average decrease reported by the company's competitors of -22.03 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -22.03 %
Kura Oncology Inc 's Comment on Competition and Industry Peers
The company operates in a highly competitive environment for the development and commercialization of new cancer treatments, facing competition from major pharmaceutical, specialty pharmaceutical, and biotechnology companies globally. Competitors often possess greater financial, technical, and human resources. Smaller and early-stage companies may also present competition, particularly through partnerships with larger firms. Mirati, now part of Bristol-Myers Squibb (BMS), is noted as a supplier of adagrasib for a combination cohort in the FIT-001 trial sponsored by the company. Competitors may develop superior products or technologies that could impact the company's financial performance and business prospects.
Strong sales growth of 36.54 % in Overall company contributed to Kura Oncology Inc increase in total revenue by 36.54 % Kura Oncology Inc improved its market share in this segment, to approximately 0.55 %.
October 18, 2025
Kura Oncology, a biopharmaceutical company specializing in oncology therapies, has recently presented promising data from its Farnesyl Transferase Inhibitor (FTI) programs at the 2025 European Society for Medical Oncology (ESMO) Congress. This new data highlights the potential of FTIs to address both innate and adaptive resistance pathways, which are often significant challenges in targeted cancer therapies.FTIs work by targeting the farnesyl transferase enzyme, playing a critical role in the post-translational modification of proteins involved in cancer cell proliferation and survival. The mechanism has shown promise in overcoming resistance that tumors may develop against existing targeted treatments, ther...
June 24, 2024
In a groundbreaking development, Kura Oncology has reported preclinical data that highlights the potential of their menin inhibitor, Ziftomenib, in the treatment of type 2 diabetes. This article aims to provide an analysis of the findings and their implications for the pharmaceutical industry, patients, and healthcare professionals.1. Context and Importance:Type 2 diabetes, a chronic disease affecting millions worldwide, is characterized by insulin resistance and the body s inability to regulate blood sugar levels effectively. Considering the growing prevalence of diabetes and its associated complications, there is a pressing need to explore novel therapeutic approaches. Kura Oncology s recent preclinical d...
February 26, 2024
Kura Oncology Takes Promising Step Forward in Combating Acute Myeloid Leukemia In a groundbreaking development, Kura Oncology has administered the first patient with a potentially life-changing drug, ziftomenib, as part of the KOMET-008 clinical trial. The trial aims to evaluate the efficacy and safety of ziftomenib in combination with various standard treatments, including FLT3 inhibitors, in patients suffering from relapsed or refractory NPM1-mutant or KMT2A-rearranged Acute Myeloid Leukemia (AML).AML is an aggressive blood cancer with limited treatment options, making this trial a significant breakthrough in providing hope for patients who have experienced relapse or have shown resistance to current thera...
NextCure Inc is a biopharmaceutical company that operates with a unique business model. They focus on discovering and developing novel immunomedicines to treat various forms of cancer and other immune-related diseases. With a focus on developing innovative therapies that target immune cells, NextCure aims to provide effective and personalized treatment options for patients in need.
Phio Pharmaceuticals Corp's business model revolves around developing and commercializing innovative RNA-based therapeutics to treat various diseases and improve patient outcomes.
Sources:
Kura Oncology Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Kura Oncology Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
